Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
38,253 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Comparison Between EGFR-TKI Efficacy in Early-Stage Non-small Cell Lung Cancer and Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.
Wang B, Yao Y, Chen Z, Wu R, Sun J, Li X, Xu X, Si Y, Liu H. · Lung · 2026 · cited 0 timesmeta-analysis, comparative study
- Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.
Zhao Y, Liu H, Meng X, Liu Z, Yu Y, Zheng Y, Sun L, Yang R, Liu J, Zhao Y, Wu L, Yang L, Zhang Z, Li M, Zhang P, Zhang Y, Zhong H, Cui J, Huang Z, Yin Y, Li M, Tong F, Xue D, Lv D, Li X, Zhang X, Chin S, Cai J, Xue T, Huang Y, Zhao H, Zhang L, TAISHAN-302 Investigators. · N Engl J Med · 2026 · cited 2 timesclinical trial, phase iii, comparative study
- Oncologic efficacy and safety of stereotactic body radiotherapy for oligometastatic non-small cell lung cancer: a systemic meta-analysis.
Jeong JU, Yoo GS, Lee JH, Chan Ahn Y, Rim CH, Chie EK, Chang AR, Korean Cancer Association Oligometastasis Working Group. · Clin Exp Metastasis · 2026 · cited 0 timesmeta-analysis, systematic review
- AdvanTIG-105: a phase I/Ib dose-expansion study of ociperlimab plus tislelizumab with or without chemotherapy in metastatic non-small cell lung cancer and extensive-stage small cell lung cancer.
Lu S, Yu Y, Zhang J, Wang Q, Cho EK, Zhao J, Kim SH, Lee Y, Clay TD, Yang TY, Chang GC, Yang H, Zuo Y, Liu R, Sun P, Kim HR. · J Immunother Cancer · 2026 · cited 0 timesOpen accessmulticenter study, clinical trial, phase i
- Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesis
Rong B, Pan H, Fu T, Liu Y, Yang P, Zhang J, Wang Y. · Front Pharmacol · cited 0 timesOpen accesssystematic-review, review
- Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Chaft JE, Sun Z, Rudin CM, Khullar OV, Simone CB, Oettel K, Kozono D, Sunkara R, Faller B, Isbell JM, Hugec V, Shipstone A, McGary EC, Clarke JM, Talsania A, Ding L, Govindan R, Sands JM, Heymach JV, Raez LE, Malik SM, Stinchcombe TE, Mandrekar SJ, Bradley J, Gerber DE, Vokes E, Gandara D, Staley C, Ramalingam SS. · JAMA · 2026 · cited 11 timesclinical trial, phase iii, comparative study
- Biomarkers of nivolumab benefit in resectable non-small cell lung cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Tanaka F, Cornelissen R, Petruzelka LB, Gao Y, Pujol JL, Ito H, de Oliveira Muniz Koch L, Ciuleanu TE, Wu L, Bohnet S, Watanabe Y, Taube JM, Deutsch JS, Erdmann CC, Meadows-Shropshire S, Neely J, Ip V, Hung YH, Sathyanarayana P, Bhatia S, Chu K, Blum SI, Lucherini S, Eddy N, Yadav A, Provencio M. · Nature · 2026 · cited 1 timesOpen accessrandomized controlled trial
- Antibody-drug conjugates in advanced small-cell lung cancer: a systematic review and single-arm meta-analysis of later-line monotherapy.
Chen X, Li S, Li H. · Front Immunol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
Rohrberg KS, Brandão M, Castañón Álvarez E, Felip E, Gort E, Hiltermann TJN, Izumi H, Kim DW, Kim SW, Paz-Ares L, Solomon B, Smit EF, Wauters E, Yoshida T, Ayyoub A, Chen HA, Colebrook S, Hamidi NN, Kuziora M, Lim K, Achour I, Drachsler MW, Karanovic D, Liu N, Cho BC. · Clin Cancer Res · 2026 · cited 1 timesOpen accessclinical trial, phase ii, multicenter study
- Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis.
Massalha I, Hijab A, Zabit R, Zidan J, Wiesel O, Peled N. · Oncoimmunology · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis.
Liu T, Song D, Chen J, Yao J, Liao J, Dang J. · PLoS One · 2026 · cited 0 timesOpen accessmeta-analysis
- Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations.
Le X, Wang J, Yu Y, Zhao Y, Planchard D, Gao B, Spira A, Liu J, Li X, Gadgeel S, Leighl N, Zhang J, Hayashi H, Nishio M, Mazieres J, de Langen AJ, Pérol M, Yoh K, Forster MD, Goto Y, de Miguel Luken M, Franco Perez FF, Chu Q, Parakh S, Nilsson MB, Jiang Y, Hu T, Wang C, Baio N, Musib L, Mounir Z, Kowanetz M, Wang S, Yea S, Hsu J, Lutzker S, Heymach JV, Juan-Vidal O, Riess JW. · Cancer Cell · 2026 · cited 1 timesclinical trial, phase i, randomized controlled trial
- Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesis.
Rong B, Pan H, Fu T, Liu Y, Yang P, Zhang J, Wang Y. · Front Pharmacol · 2026 · cited 0 timessystematic review
- Population Pharmacokinetics and Exposure-response Analysis of Durvalumab in Patients with Limited-stage Small-cell Lung Cancer in the Phase 3 ADRIATIC Study.
Su H, Zhao BJ, Fu Y, Zhang YY, Chugh P, Casson E, Lim K, Ren S, Zhou D, Ma P, Fan C. · AAPS J · 2026 · cited 0 timesclinical trial, phase iii, randomized controlled trial
- First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.
Ichimura T, Sugita H, Noma H, Yamaji N, Sunaga T, Sato MT, Maeda M, Toyoda S, Ota E, Hasegawa T. · Cochrane Database Syst Rev · 2026 · cited 1 timessystematic review, network meta-analysis
- Nab-paclitaxel or Paclitaxel Treatment for Relapsed Small Cell Lung Cancer: A Single-arm Meta-analysis.
Kubo S, Somekawa K, Nagaoka S, Matsumoto S, Eguchi K, Matsushita S, Kajita Y, Muraoka S, Yang F, Kaneko A, Tanaka K, Fujii H, Horita N, Hara YU, Kobayashi N. · Anticancer Res · 2026 · cited 0 timesmeta-analysis, systematic review
- Advances in Aptamer Diagnostics Targeting Non-Small-Cell Lung Cancer: A Systematic Review.
Agnello L, Leone I, Affinito A, Esposito CL, Catuogno S, D'Agostino A, Salvatore M, Condorelli G, Nuzzo S. · Int J Mol Sci · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Discordance of PD-L1 expression between primary and paired metastatic non-small cell lung cancer: a systematic review and meta-analysis.
Zhang L, Gao Y, Wang X, Gu Y, Hou L, Wang X. · Front Immunol · 2026 · cited 0 timesOpen accessmeta-analysis, research support, non-u.s. gov't
- Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes.
Oliveira R, Halvorsen T, Killingberg K, Emdal EF, Dale VG, Grønberg BH, Sætrom P. · Lung Cancer · 2026 · cited 0 timesrandomized controlled trial
- Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial.
Yue D, Cappuzzo F, Wang W, Liu H, Chen Q, Wang S, Leaw SJ, Yao B, Barnes FB, Barnes G, Wang C. · Future Oncol · 2026 · cited 0 timesOpen accessclinical trial, phase iii, multicenter study
- A Systematic Review and Meta-analysis of Clinical Trials in ALK-positive Non-small Cell Lung Cancer.
Basmajian K, Stepanyan Z, Sarkissian S. · Anticancer Res · 2026 · cited 0 timesmeta-analysis, systematic review
- Clinical outcomes of targeted treatment strategies for primary non-small cell lung cancer with MET alterations: a systematic review and meta-analysis.
Meng Z, Deng H, Han J, Ruan W, Xiao Y, Huang H, Wang J, Huang J. · Front Oncol · 2026 · cited 0 timessystematic review
- Stage II Non-Small Cell Lung Cancer: Upfront Surgery or Neoadjuvant Chemoimmunotherapy.
Tajè R, Gallina FT, Spicer JD. · Ann Thorac Surg · 2026 · cited 1 timesmeta-analysis, review
- The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies.
Li Z, Wang X, Shi Q, Guo Y, Dong G, Liu Z. · Front Pharmacol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A).
Zhang P, Wang D, He W, Zhang H, Dong Y, Situ Y, Wang M, Zhang Y, Wei S, Qiu B, Huang Y, Liu H. · J Immunother Cancer · 2026 · cited 0 timesOpen accessclinical trial, phase ii, randomized controlled trial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.